Adam Farkas,
Thanks again for presenting the webinar.
For anyone that is going to view it, it is a full two hours. Give it 15 or 20 minutes to get going - then I really think you will enjoy the course and learn something.
I gave this talk on April 14 and because of my inexperience with the technology, I made a couple of mistakes in the presentation. First, I said the treatment is customized to the patient based on the test results. At least with the AllerFocus product, that is not true and they have a standard, uniform panel.
Fortunately, that fact does not appear to matter very much. The AllerFocus serum (i.e., sublingual drops) is a broad spectrum preparation as opposed to a patient-specific preparation; but, since I am a new allergist, that is good enough for me right now.
If I am understanding things properly, patient-specific therapy is expensive and is delivered via injection only in the allergist's office. As always, I am the type of doctor that believes some therapy is better than no therapy so again, this is good enough for me right now.
In addition, I made comments in the presentation that "now" we could do this diagnostic test where before, we could not.
That is not true.
We could always do the test (at least in Texas) - the problem was getting paid.
The insurance companies would not pay us because we are optometrists.
That is the part that has changed - at least for Medicare and most of the private payors.
It never had anything to do with the Texas Optometry Board.
As a matter of fact, if you call the Texas Optometry Board and ask them if it's OK to perform diagnostic allergy skin testing to assist in the differential diagnosis of allergic conjunctivitis, they will tell you that they do not interpret Texas Optometry Board rules over the phone and you should read the rules for yourself, consult your attorney if you don't understand the rules, and as the preachers say, "govern yourselves accordingly."
That is what they will tell you so please do not call them.
Optometrists that practice in Texas, DO NOT CALL THE TEXAS OPTOMETRY BOARD and ask them if it is OK to perform diagnostic skin testing to assist in the differential diagnosis of allergic conjunctivitis. If you have questions, call me at 972-658-0545.
Last thing, I said the sublingual immunotherpay that we can do is FDA approved. That is not true, but again, fortunately, it does not matter.
The antigen serum that comprises the sublingual immunotherapy is FDA-approved, but the approval designates that the therapy be delivered intravenously - not via the sublingual route. Therefore, even though the serum is manufactured in an FDA-approved facility and in an FDA-approved manner, because of the delivery method (i.e., sublingual), its use is considered "off-label" when the therapy is delivered in that manner.
The only thing that means is that insurance will not cover the cost of the drops, whereas they will cover the cost of the injections. I wonder how that happened?
Anyway, those are my corrections.
Fast forward - I have tested 4 patients since the lecture and have prescribed immunotherapy for one of those patients.
This has started off very well. The staff understands what we are trying to do for our patients and my limited sample size of patients has been very enthusiastic about the test and the impact the results have on their health-related decision-making going forward.
That is all...